FDA Opens Public Comment on Generative AI Medical Device Rules

The U.S. Food and Drug Administration has published a discussion paper outlining potential regulatory approaches for generative AI-enabled medical devices and is soliciting public feedback through October 19, 2026.

The paper, titled "Considerations for the Regulation of Generative AI-Enabled Medical Devices," addresses how the agency might assess risk, conduct premarket evaluations, and implement postmarket monitoring for devices that use generative AI technologies. The initiative is led by the Digital Health Center of Excellence within the FDA's Center for Devices and Radiological Health.

A framework for emerging technology

According to Acting FDA Commissioner Kyle Diamantas, the effort reflects the agency's commitment to advancing innovation while ensuring safe deployment of AI in healthcare settings. The discussion paper acknowledges that generative AI-enabled medical devices differ substantially from traditional regulated devices due to their broad capabilities, diverse characteristics, and novel risk profiles.

The FDA proposes a two-axis framework for risk assessment that would inform regulatory expectations. The paper also explores possible approaches to premarket evaluation and what the agency calls "risk-proportionate postmarket monitoring" — suggesting that oversight intensity would scale with the level of potential harm.

Why it matters

As generative AI tools move from research labs into clinical practice — drafting radiology reports, suggesting treatment protocols, or analyzing patient data — regulators face the challenge of creating guardrails without stifling innovation. The FDA's framework could establish a template for how health authorities worldwide approach AI medical devices, particularly those that generate novel outputs rather than simply analyzing existing data. The public comment period signals the agency's recognition that input from clinicians, developers, and patients is essential before finalizing any regulatory pathway.

Targeted questions guide feedback

Throughout the discussion paper, the FDA poses specific questions designed to elicit stakeholder input on the proposed framework. These questions will inform the development of formal regulatory guidance.

"Generative AI-enabled medical devices are poised to reshape the health technology landscape, and the FDA has an important responsibility to provide thoughtful leadership for this new era," said Rick Abramson, Director of the FDA Digital Health Center of Excellence. "This discussion paper advances the frontiers of regulatory science and propels a critical conversation about how to enable beneficial innovation, protect public health, and preserve trust."

Michelle Tarver, Director of the FDA Center for Devices and Radiological Health, emphasized that the agency is launching "a transparent process to inform the development of an approach that safeguards patients and consumers, advances innovation, and serves as a potential model for regulators around the world."

The FDA clarified that the discussion paper is not draft or final guidance but rather a starting point for dialogue among stakeholders. Public comments must be submitted by October 19, 2026.

These details were first reported by The ASCO Post.